COVID-19 TREATMENT -CURRENT PROTOCOLS AND FUTURE PROSPECTS

Authors

  • Ana Carolina Pires Ferreira
  • Samili Matos Garcias Lopes
  • Sandra Ribeiro de Morais
  • Cristiene Costa Carneiro UNIP

DOI:

https://doi.org/10.47820/recima21.v2i4.251

Keywords:

drug treatment, coronavirus, health

Abstract

Considering the relevance of covid-19 today, this study aimed to point out the main drugs that have become the target of study and clinical use in the treatment of the disease. The literature narrative review methodology on treatments previously tested for covid-19 was used, bringing together the most relevant and robust studies on each drug. Of the drugs evaluated, some had a positive influence on the healing time and reduction of symptoms caused by the disease. Among the drugs studied, remdesivir was the most prominent, reducing the time spent in the ICU and also the mortality rate. Heparin had a great positive influence linked to cases with a tendency to develop thrombosis. Dexamethasone demonstrated the power to reduce the chance of mortality and ivermectin acted in reducing the duration of the disease. Other drugs such as Azithromycin and Hydroxychloroquine have not been shown to be effective in studies of greater relevance and no data has been found to justify their use for the treatment of Covid-19. Despite the small amount of data to prove its effect against Covid-19, have shown positive potential and reduced the length of stay of patients in the hospital. To date, no specific medications have been approved to treat covid-19. The treatment of the disease focuses mainly on supportive care. However, Our bibliographic research has shown that some protocols demonstrate a positive outcome when compared to treatment without the use of any drugs.

Downloads

Download data is not yet available.

Published

16/05/2021

How to Cite

Pires Ferreira, A. C., Matos Garcias Lopes, S. ., Ribeiro de Morais , S., & Costa Carneiro, C. (2021). COVID-19 TREATMENT -CURRENT PROTOCOLS AND FUTURE PROSPECTS. RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218, 2(4), e24251. https://doi.org/10.47820/recima21.v2i4.251